Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

ClinicalTrials.gov ID: NCT03045406

Public ClinicalTrials.gov record NCT03045406. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 5:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study

Study identification

NCT ID: NCT03045406
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Fadoi Foundation, Italy; Other
Enrollment: 1,170 participants

Conditions and interventions

Conditions

Venous Thromboembolism

Interventions

Apixaban Drug
Dalteparin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 12, 2017
Primary completion: May 31, 2019
Completion: Nov 30, 2019
Last update posted: Jun 23, 2025

2017 – 2019

United States locations

U.S. sites: 18
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
University of Southern California	Los Angeles	California	90089	—
Georgetown University	Washington D.C.	District of Columbia	20007	—
University of Florida	Gainesville	Florida	32610	—
Jacksonville Center for Clinical Research	Jacksonville	Florida	32207	—
Mayo Clinic Jacksonville	Jacksonville	Florida	32224	—
Emory University	Atlanta	Georgia	30322	—
Brigham and Women's Hospital/DFCI	Boston	Massachusetts	02115	—
Massachusetts General Hospital	Boston	Massachusetts	02214	—
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
Mayo Clinic	Rochester	Minnesota	55905	—
Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire	03756	—
New York-Presbyterian Hospital	New York	New York	10021	—
Staten Island University Hospital/Northwell Health	Staten Island	New York	10305	—
Albert Einstein College of Medicine	The Bronx	New York	10467	—
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	—
Duke University Medical Center	Durham	North Carolina	27710	—
Ohio State University	Columbus	Ohio	43210	—
University of Texas M.D. Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 109 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03045406, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 23, 2025 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03045406 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →